Tempus AI has acquired Paige for an undisclosed amount, bringing together two significant players in the application of artificial intelligence to oncology. Paige specializes in leveraging AI to advance cancer discovery and treatment, offering a cloud-based platform that enhances pathologists’ workflow, increases diagnostic confidence, and improves productivity globally. Notably, Paige is the first company to receive FDA approval for a clinical AI application in digital pathology, and its technology supports pharmaceutical companies in evaluating treatment options and designing new biomarkers for drug development.
This acquisition represents a strategic move for Tempus AI, a company focused on accelerating precision medicine through its AI-powered platform for data aggregation and analysis in healthcare, particularly in cancer care. By buying Paige, Tempus AI gains its robust, FDA-approved digital pathology AI solutions and its established presence in clinical diagnostics and life sciences research. The integration of Paige’s specialized AI capabilities directly complements Tempus AI’s mission to provide comprehensive, data-driven insights for oncologists and researchers.
The combination is expected to create significant synergies, strengthening Tempus AI's offerings by integrating Paige’s advanced diagnostic AI and pathology platform. This will allow for a more holistic approach to cancer care, from initial diagnosis through treatment selection and drug development. Paige’s technology for identifying molecular biomarkers from tissue samples will also enhance Tempus AI’s efforts in precision oncology, helping to deliver more precise treatment options for patients.
Looking ahead, the combined entity aims to accelerate the development and deployment of AI-powered solutions across the cancer care continuum, driving further innovation in diagnostics, biomarker discovery, and personalized therapeutic strategies. This acquisition positions Tempus AI to offer an even more comprehensive and integrated suite of tools for transforming patient outcomes in oncology.